Conventional treatments for the arthritides do little to affect the underlying disease processes. It is widely accepted that non-steroidal anti-inflammatory drugs only dampen down the inflammatory response and increasingly recog Consequently, intense research efforts are being made to determine the protein structure of the individual MMPs and TIMPs.10 "1 The long term goal of this research is to discover precisely how TIMPs are able to block the activity of the MMPs, to mimic this action using low molecular weight chemicals, and so develop therapeutic agents that can block the destruction of connective tissue in the rheumatic diseases. But which is the correct MMP to block? Some workers consider that the early loss of proteoglycan from cartilage tissue should be prevented to avoid cartilage damage and that inhibitors targeted to proteoglycan degrading enzymes would be the most useful. Others have proposed that while proteoglycan can be rapidly lost from the tissues, it can also be rapidly replaced,"7 and the loss of cartilage collagen marks the beginning of irreversible cartilage damage. Consequently, some workers propose that the target enzyme should be collagenase, and inhibitors that are specific for this enzyme should prevent the cartilage destruction seen in the arthritides.
Difficulties do remain. Effective inhibitors must be orally active: as their structures are based on peptide sequences these are often degraded and inactivated by gut peptidases. Although some biostable inhibitors have been synthesised, improvements could still be made. Once the structures of the MMPs and TIMPs are known, and the mechnism of inhibition understood, it should be easier to design structures that are more stable. Some workers are concerned that these compounds will interfere with the normal turnover of connective tissues. It is hoped that the rate of degradation will be slowed in the presence of inhibitors without completely blocking normal turnover.
It will be hard to assess rapidly the effectiveness of these drugs in preventing cartilage loss unless improved techniques are developed to detect cartilage destruction. The current hopes for magnetic resonance imaging are high. Also, if destruction of cartilage is intermittent then it would be very beneficial to have markers that identify those patients that are rapidly degrading cartilage at the time of treatment. These patients could then be recruited into trials of these compounds and should show the maximum benefit. 
